💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sacubitril-Valsartan

Phase 4 Aprovado Small molecule
Half-Life
11.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
414.5 g/mol
LogP
—
Phase
4

Sacubitril-valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) combining sacubitril (a neprilysin inhibitor prodrug) and valsartan (an angiotensin II receptor blocker) for heart failure treatment. Sacubitril inhibits neprilysin-mediated breakdown of natriuretic peptides, bradykinin, and other vasoactive substances, while valsartan blocks AT1 receptors, producing complementary vasodilatory and cardioprotective effects. It has demonstrated superior outcomes to ACE inhibitors in patients with heart failure with reduced ejection fraction.

Peso Molecular

414,5010 g/mol

TPSA

205,00 Ų

Áreas Terapêuticas

Thyroid Cancer Cardiovascular Disease Systemic Lupus Erythematosus Chronic Kidney Disease Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer HIV/AIDS Heart Failure Atrial Fibrillation

Classes de Medicamentos

C — C - Cardiovascular System

Mecanismo de Ação

Angiotensin receptor-neprilysin inhibitor (ARNI) combining neprilysin inhibition with AT1 receptor blockade.

Pharmacokinetics (PK)

Half-Life 11.5 hours

Pharmacodynamics (PD)

Mecanismo

Angiotensin receptor-neprilysin inhibitor (ARNI) combining neprilysin inhibition with AT1 receptor blockade.

SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O.CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O

InChI

InChI=1S/C24H29N5O3.C24H29NO5/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t22-;17-,21+/m01/s1

Molecular Formula

C24H29N2O5

HBD / HBA

4 / 11

Ligações Rotacionáveis

22

Átomos Pesados

62

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Sacubitril-valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) combining sacubitril (a neprilysin inhibitor prodrug) and valsartan (an angiotensin II receptor blocker) for heart failure treatment. Sacubitril inhibits neprilysin-mediated breakdown of natriuretic peptides, bradykinin, and other vasoactive substances, while valsartan blocks AT1 receptors, producing complementary vasodilatory and cardioprotective effects. It has demonstrated superior outcomes to ACE inhibitors in patients with heart failure with reduced ejection fraction.

Angiotensin receptor-neprilysin inhibitor (ARNI) combining neprilysin inhibition with AT1 receptor blockade.

Key pharmacokinetic parameters for Sacubitril-Valsartan: Half-life: 11.5 hours.

Yes, Sacubitril-Valsartan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

ADME Journey →

Related Drugs

Same Drug Class

Atorvastatin Small molecule Amlodipine Small molecule Lisinopril Small molecule Metoprolol Small molecule
{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • PubChem — National Center for Biotechnology Information (NCBI). CID 24755620. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.